All Stories

  1. Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis

    Article • Frontiers in Endocrinology, March 2026, Frontiers

    Dr Antonio C Bossi

  2. Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study

    Article • Endocrine Practice, February 2026, Elsevier

    Dr Antonio C Bossi

  3. Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data

    Article • Diabetes Obesity and Metabolism, September 2025, Wiley

    Dr Antonio C Bossi, Prof Marco Giorgio Baroni

  4. Continuous Interstitial Glucose Monitoring through a Long-Term Subcutaneous Implantable Sensor during Pregnancy in Type 1 Diabetes: A Two- Patient Case Report

    Article • Endocrine Metabolic & Immune Disorders - Drug Targets, August 2025, Bentham Science Publishers

    Dr Antonio C Bossi

  5. Unraveling the Puzzle of Bone Health in Klinefelter Syndrome: Association Between DXA‐Derived Lumbar Bone Strain Index and Body Composition Parameters in a Single Center Cohort

    Article • Clinical Endocrinology, July 2025, Wiley

    Dr Antonio C Bossi

  6. Long‐term preservation of kidney function with SGLT‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease

    Article • Diabetes Obesity and Metabolism, July 2025, Wiley

    Prof Marco Giorgio Baroni, Dr Antonio C Bossi

  7. Diabetic Ketoacidosis: Considerations and Residual Controversies in Management After the 2024 ADA, EASD, JBDS, AACE, and DST Joint Consensus

    Article • Endocrine Metabolic & Immune Disorders - Drug Targets, April 2025, Bentham Science Publishers

    Dr Antonio C Bossi

  8. Anogenital distance in Klinefelter syndrome: A case‐control study

    Article • Andrology, March 2025, Wiley

    Dr Antonio C Bossi

  9. Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study

    Article • Journal of Endocrinological Investigation, January 2025, Springer Science + Business Media

    Dr Antonio C Bossi

  10. IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study

    Article • Acta Diabetologica, September 2024, Springer Science + Business Media

    Dr Antonio C Bossi

  11. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies

    Article • European Journal of Endocrinology, July 2024, Oxford University Press (OUP)

    Dr Antonio C Bossi

  12. COVID-19 vaccines and blood glucose control: Friend or foe?

    Article • Human Vaccines & Immunotherapeutics, June 2024, Taylor & Francis

    Dr Antonio C Bossi

  13. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk

    Article • The Lancet Regional Health - Europe, March 2024, Elsevier

    Prof Marco Giorgio Baroni, Dr Antonio C Bossi

  14. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    Article • The Lancet, January 2024, Elsevier

    Professor Erkin Mirrakhimov, Angelina Passaro, Dr Antonio C Bossi

  15. Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study

    Article • Atherosclerosis, November 2023, Elsevier

    Angelina Passaro, Dr Antonio C Bossi

  16. Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors

    Article • Journal of Endocrinological Investigation, October 2023, Springer Science + Business Media

    Dr Antonio C Bossi

  17. Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors

    Article • Journal of Endocrinological Investigation, August 2023, Springer Science + Business Media

    Dr Antonio C Bossi

  18. Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

    Article • Journal of the American Heart Association, May 2023, Wolters Kluwer Health

    Angelina Passaro, Dr Antonio C Bossi

  19. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

    Article • Journal of Endocrinological Investigation, January 2023, Springer Science + Business Media

    Dr Antonio C Bossi

  20. Serum testosterone mirrors inflammation parameters in females hospitalized with COVID-19

    Article • Journal of Endocrinological Investigation, November 2022, Springer Science + Business Media

    Dr Antonio C Bossi

  21. Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial)

    Article • Diabetes Research and Clinical Practice, March 2022, Elsevier

    Dr Antonio C Bossi

  22. Patient-Support Program in Diabetes Care During the Covid-19 Pandemic: An Italian Multicentric Experience

    Article • Patient Preference and Adherence, January 2022, Taylor & Francis

    Dr Antonio C Bossi

  23. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

    Article • The Lancet, November 2021, Elsevier

    Professor Erkin Mirrakhimov, Prof. MD., PhD., EuSpLM Tomáš Šálek, Angelina Passaro, Dr Antonio C Bossi

  24. Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial

    Article • Acta Diabetologica, October 2021, Springer Science + Business Media

    Dr Antonio C Bossi

  25. Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study

    Article • PLoS Medicine, July 2021, PLOS

    Dr Antonio C Bossi

  26. Correction to: Screening of postpartum diabetes in women with gestational diabetes: high‑risk subgroups and areas for improvements—the STRONG observational study

    Article • Acta Diabetologica, June 2021, Springer Science + Business Media

    Dr Antonio C Bossi

  27. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes

    Article • Cardiovascular Diabetology, May 2021, Springer Science + Business Media

    paola berchialla, Dr Antonio C Bossi

  28. Screening of postpartum diabetes in women with gestational diabetes: high-risk subgroups and areas for improvements—the STRONG observational study

    Article • Acta Diabetologica, April 2021, Springer Science + Business Media

    Dr Antonio C Bossi

  29. Association of Obesity With Survival Outcomes in Patients With Cancer

    Article • JAMA Network Open, March 2021, American Medical Association (AMA)

    Dr Antonio C Bossi

  30. Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis

    Article • Canadian Journal of Diabetes, March 2021, Elsevier

    Dr Antonio C Bossi

  31. Effects of hypertension on cancer survival: A meta‐analysis

    Article • European Journal of Clinical Investigation, February 2021, Wiley

    Dr Antonio C Bossi

  32. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study

    Article • Journal of Internal Medicine, December 2020, Wiley

    Dr Antonio C Bossi

  33. Grey zones sul diabete mellito in ambito cardiologico. Opinioni degli esperti

    Article • Giornale Italiano di Cardiologia, December 2020, Il Pensiero Scientifico Editore

    Dr Antonio C Bossi

  34. A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions

    Article • Diabetes Therapy, October 2020, Springer Science + Business Media

    Dr Antonio C Bossi

  35. ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide

    Article • Diabetes Therapy, September 2020, Springer Science + Business Media

    Dr Antonio C Bossi, Giovanni Veronesi

  36. PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

    Article • BMJ Open Diabetes Research & Care, September 2020, BMJ

    Dr Antonio C Bossi

  37. Prescription of Sulphonylureas among Patients with Type 2 Diabetes Mellitus in Italy: Results from the Retrospective, Observational Multicentre Cross-Sectional SUSCIPE (Sulphonyl_UreaS_Correct_Internal_Prescription_Evaluation) Study

    Article • Diabetes Therapy, July 2020, Springer Science + Business Media

    Dr Antonio C Bossi

  38. Insulin Management for Type 1 Diabetic Patients During Social Alcohol Consumption: The SPRITZ Study

    Article • Current Diabetes Reviews, June 2020, Bentham Science Publishers

    Dr Antonio C Bossi, Giovanni Veronesi

  39. Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends

    Article • Diabetes Therapy, May 2020, Springer Science + Business Media

    Dr Antonio C Bossi

  40. Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients

    Article • May 2020, openRxiv

    Dr Antonio C Bossi

  41. Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes—TOSCA.IT Study

    Article • Nutrients, December 2019, MDPI AG

    Dr Antonio C Bossi, Dr Marilena Vitale

  42. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

    Article • Journal of Endocrinological Investigation, September 2019, Springer Science + Business Media

    Dr Antonio C Bossi

  43. Similar effectiveness of dapagliflozin and GLP‐1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study

    Article • Diabetes Obesity and Metabolism, August 2019, Wiley

    paola berchialla, Dr Antonio C Bossi

  44. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes

    Article • Frontiers in Genetics, July 2019, Frontiers

    Dr Antonio C Bossi

  45. Changes in the Prescription of Glucose‐Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study

    Article • Journal of the American Heart Association, July 2019, Wolters Kluwer Health

    Dr Antonio C Bossi

  46. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial

    Article • Diabetes Obesity and Metabolism, February 2019, Wiley

    Dr Antonio C Bossi

  47. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study

    Article • Atherosclerosis, October 2018, Elsevier

    Dr Angela Pirillo, Dr Antonio C Bossi

  48. The risk stratification of adverse neonatal outcomes in women with gestational diabetes (STRONG) study

    Article • Acta Diabetologica, September 2018, Springer Science + Business Media

    Dr Antonio C Bossi

  49. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study

    Article • Acta Diabetologica, August 2018, Springer Science + Business Media

    Dr Antonio C Bossi

  50. Efficacy, safety and acceptability of the new pen needle 34G × 3.5 mm: a crossover randomized non-inferiority trial; AGO 02 study

    Article • Current Medical Research and Opinion, July 2018, Taylor & Francis

    Dr Antonio C Bossi

  51. Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study

    Article • Diabetes Therapy, June 2018, Springer Science + Business Media

    Dr Antonio C Bossi

  52. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion

    Article • Nutrition Metabolism and Cardiovascular Diseases, April 2018, Elsevier

    Dr Antonio C Bossi

  53. Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial

    Article • Journal of the Endocrine Society, March 2018, Endocrine Society

    Dr Antonio C Bossi

  54. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting

    Article • Acta Diabetologica, March 2018, Springer Science + Business Media

    Dr Antonio C Bossi

  55. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial

    Article • The Lancet Diabetes & Endocrinology, January 2018, Elsevier

    Dr Antonio C Bossi

  56. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study

    Article • Advances in Therapy, December 2017, Springer Science + Business Media

    Dr Antonio C Bossi

  57. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

    Article • The Lancet Diabetes & Endocrinology, November 2017, Elsevier

    Dr Marilena Vitale, Dr Antonio C Bossi

  58. La gestione del paziente diabetico tra presente e futuro

    Article • AboutOpen, October 2017, Aboutscience Srl

    Dr Antonio C Bossi

  59. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

    Article • Atherosclerosis Supplements, October 2017, Elsevier

    Dr Angela Pirillo, Dr Antonio C Bossi

  60. Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)

    Article • Atherosclerosis Supplements, October 2017, Elsevier

    Dr Antonio C Bossi

  61. Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study

    Article • Zeitschrift für Ernährungswissenschaft, December 2016, Springer Science + Business Media

    Dr Antonio C Bossi

  62. A Prospective Study for Introducing Insulin Pens and Safety Needles in a Hospital Setting. The SANITHY Study

    Article • Current Diabetes Reviews, October 2016, Bentham Science Publishers

    Dr Antonio C Bossi, Giovanni Veronesi

  63. Skin Oil Staining to Avoid Infusion Set Cannula Crimping

    Article • Journal of Diabetes Science and Technology, September 2016, SAGE Publications

    Dr Antonio C Bossi

  64. Comment on Muraki et al. Potato Consumption and Risk of Type 2 Diabetes: Results From Three Prospective Cohort Studies. Diabetes Care 2016;39:376–384

    Article • Diabetes Care, August 2016, American Diabetes Association

    Dr Antonio C Bossi

  65. PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment

    Article • BMJ Open Diabetes Research & Care, July 2016, BMJ

    Dr Antonio C Bossi

  66. Determinants of nurse satisfaction using insulin pen devices with safety needles: an exploratory factor analysis

    Article • Clinical Diabetes and Endocrinology, November 2015, Springer Science + Business Media

    Dr Antonio C Bossi, Giovanni Veronesi

  67. Continuous Subcutaneous Insulin Infusion in Italy: Third National Survey

    Article • Diabetes Technology & Therapeutics, February 2015, Mary Ann Liebert Inc

    Dr Antonio C Bossi, Prof Marco Giorgio Baroni

  68. Efficacy, safety and acceptability of the new pen needle 33G × 4 mm. AGO 01 study

    Article • Current Medical Research and Opinion, December 2014, Informa Healthcare

    Dr Antonio C Bossi

  69. GLP-1 response to 2 energy-matched snacks

    Article • American Journal of Clinical Nutrition, October 2014, American Society for Nutrition

    Dr Antonio C Bossi

  70. Lo studio SAVOR-TIMI 53

    Article • Giornale Italiano di Cardiologia, June 2014, Il Pensiero Scientifico Editore

    Dr Antonio C Bossi

  71. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial

    Article • The Lancet Diabetes & Endocrinology, September 2013, Elsevier

    Dr Antonio C Bossi

  72. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

    Article • Kidney International, July 2013, Elsevier

    Dr Antonio C Bossi

  73. ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy

    Article • Diabetes, June 2013, American Diabetes Association

    Dr Antonio C Bossi

  74. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial

    Article • Nutrition Metabolism and Cardiovascular Diseases, November 2012, Elsevier

    Dr Antonio C Bossi

  75. Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes

    Article • Journal of the American Society of Nephrology, August 2012, American Society of Nephrology

    Dr Antonio C Bossi

  76. Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes

    Article • Diabetes Care, July 2012, American Diabetes Association

    Dr Antonio C Bossi

  77. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

    Article • Diabetes Care, May 2012, American Diabetes Association

    Dr Antonio C Bossi, Prof Marco Giorgio Baroni, Ponnusamy Saravanan

  78. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial

    Article • Hypertension, September 2011, Wolters Kluwer Health

    Dr Antonio C Bossi

  79. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

    Article • European Journal of Pharmacology, September 2011, Elsevier

    Dr Antonio C Bossi, Dr Aldo Bonaventura

  80. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial

    Article • Journal of Hypertension, February 2011, Wolters Kluwer Health

    Associate Professor Borislav D Dimitrov, Dr Antonio C Bossi

  81. Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A prospective randomized double-blind clinical trial

    Article • Diabetes Care, June 2010, American Diabetes Association

    Dr Antonio C Bossi

  82. Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial

    Article • Journal of Ophthalmology, January 2010, Hindawi Publishing Corporation

    Dr Antonio C Bossi

  83. Impact of the PPAR- 2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT

    Article • Diabetes, August 2009, American Diabetes Association

    Dr Antonio C Bossi

  84. Bent Needles: Another Problem in Glycemic Control

    Article • Diabetes Care, September 2008, American Diabetes Association

    Dr Antonio C Bossi

  85. Preventing Microalbuminuria in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2004, New England Journal of Medicine (NEJM/MMS)

    Dr Antonio C Bossi

  86. Ondasentron in the Treatment of Diabetic Diarrhea

    Article • Diabetes Care, May 1994, American Diabetes Association

    Dr Antonio C Bossi

  87. Side-effects, structure, and H2-receptor antagonists

    Article • The Lancet, May 1992, Elsevier

    Dr Antonio C Bossi

  88. Epidural Spinal Electrostimulatory System (ESES) in the Management of Diabetic Foot and Peripheral Arteriopathies

    Article • Pacing and Clinical Electrophysiology, April 1989, Wiley

    Dr Antonio C Bossi

  89. UNCOATED VERSUS COATED 5-AMINOSALICYLIC ACID IN CROHN'S DISEASE

    Article • The Lancet, February 1989, Elsevier

    Dr Antonio C Bossi

  90. Ano-rectal manometry as an evaluating test for impaired ano-rectal function in diabetes mellitus

    Article • October 1986, Springer Science + Business Media

    Dr Antonio C Bossi

  91. Clinical and instrumental diagnosis of autonomic neuropathy in insulin-dependent diabetes

    Article • October 1982, Springer Science + Business Media

    Dr Antonio C Bossi